My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2009-05-19_REVISION - M1977416 (29)
DRMS
>
Day Forward
>
Revision
>
Minerals
>
M1977416
>
2009-05-19_REVISION - M1977416 (29)
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
6/15/2021 2:18:35 PM
Creation date
5/27/2009 2:19:22 PM
Metadata
Fields
Template:
DRMS Permit Index
Permit No
M1977416
IBM Index Class Name
REVISION
Doc Date
5/19/2009
Doc Name
EPP(AM-01) Att 4: Bioavailability; Att 5: Water Bal; Att 6: Percolation; Att 7: Lab Rpts. (part 4)
From
Denison Mines
To
DRMS
Type & Sequence
AM1
Email Name
RCO
Media Type
D
Archive
No
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
162
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
The site-specific relative bioavailability (RBA) can be used to adjust RMC screening values for a <br />site by modifying the reference dose (RfD) and/or oral slope factor (SFo) for arsenic to account • <br />for differences in absorption between arsenic ingested in soil as follows (EPA 1997): <br />HfAlefavir <br />1VREA and 5d1'Qadf ? S"defoulr X REA <br />Given that the RBA value is less than one, the adjusted RfD value will increase and the SFo will <br />decrease. Reviewing the noncarcinogenic and carcinogenic RMC calculations presented above, <br />it can be readily seen that the use of a site-specific bioavailability factor will adjust the RMC <br />values upward as discussed in the BLM guidance document (BLM 2004). <br />It should be noted that for arsenic, the IVBA test conditions have not yet been optimized. <br />Accordingly, EPA Region 8 recommends a weight-of-evidence approach that combines the in <br />vitro studies and geochemical speciation results (e.g., via use of an electron microscope) with <br />the in vivo and geochemical results from the library of in vivo studies on arsenic bioavailability <br />(ESTCP 2008). For example, if RBA for arsenic in site soils was observed to be 20 percent, and <br />electron microprobe analysis showed geochemistry consistent with low bioaccessibility, results <br />would strongly support downward adjustment of the bioavailability term, which would result <br />in increase RMC This approach was utilized to assess RBA for arsenic at the Sunday Mines <br />Group. <br />References <br />CDM Inc. (CDM). 2009. Telephone Conversation and Email, Mark Nelson (CDM) and Dr. Karl Ford <br />(BLM). January 6. <br />SERDP and ESTCP Expert Panel Workshop on Research and Development Needs for Understanding <br />and Assessing the Bioavailability of Contaminants in Soils and Sediments. November. <br />U.S. Bureau of Land Management (BLM). 2004. Rick Management Criteria for Metals at BLM <br />Mining Sites. Technical Note 390 Rev. October. <br />U.S. Environmental Protection Agency (EPA). 1997. Relative Bioavailability of Arsenic in Mining <br />Wastes, EPA Region 8 Document. December. <br />0
The URL can be used to link to this page
Your browser does not support the video tag.